Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1756-1764

  Tannock, I F ^a   Osoba, D ^a   Stockler, M R ^a   Ernst, D S ^a   Neville, A J ^a   Moore, M J ^a   Armitage, G R ^a   Wilson, J J ^a   Venner, P M ^a   Coppin, C M ^a   Murphy, K C ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; MITOXANTRONE; PREDNISONE; PROCHLORPERAZINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANADA; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 8944220720     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1756     Document Type: Article

References (28)

1. Hudes GR, Greenberg R, Krigel RL, et al: Phase I study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
2. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
3. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
4. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. JNCI 85:611-621, 1993
5. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
6. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
7. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
8. Moore MJ, Osoba D, Murphy K, et al: Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994
9. Osborne CK, Drelichman A, Von Hoff DD, et al: Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 67:1133-1135, 1983
10. Kantoff PW, Block C, Letvak L, et al: 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am J Clin Oncol 16:489-491, 1993
11. Dupont A, Gomez J-L, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993
12. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
13. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
14. Melzack R: The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1:277-299, 1975
15. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. JNCI 85:365-376, 1993
16. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality Life Res 3:353-364, 1994
17. Aitkin M: A note on the regression analysis of censored data. Technometrics 23:161-163, 1981
18. Mallows CL: Some comments on Cp. Technometrics 15:661-675, 1973
19. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
20. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
21. Raghavan D, Cox K, Pearson BS, et al: Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 72:625-628, 1993
22. Fossa SD, Aaronson NK, Newling D, et al: Quality of life and treatment of hormone resistant metastatic prostate cancer. Eur J Cancer 26:1133-1136, 1990
23. Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 113:147-154, 1990
24. Goodwin PJ, Feld R, Evans WK, et al: Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 6:1537-1547, 1988
25. Fossa SD, Dearnaley DP, Law M, et al: Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3:361-366, 1992
26. Fossa SD: Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: Single institution experience. Br J Urol 74:345-351, 1994
27. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833-1838, 1992
28. Coates A, Thomson D, McLeod GRM, et al: Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A: 1731-1734, 1993